• Health and sustainable development: A recent report by Impact Global Health demonstrates that targeted biomedical R&D in neglected, poverty-related diseases will save over 40 million lives and prevent 2.83 billion disability-adjusted life years (DALYs) between 2000 and 2040. Every euro invested generates a return of 405 euros worldwide  by reducing downstream healthcare costs and massive productivity losses. As a leading global health supporter, Germany's proportional financial contribution is estimated to save nearly 600,000 lives worldwide, prevent over 40 million DALYs, and generate a direct societal benefit of more than 650 million euros.
• Innovation and economic value: Public research funding exerts  substantial economic benefits on gross domestic product (GDP). Every euro invested in innovation-oriented public spending generates between €9.6 and €15.3 in GDP after five years, while generic government spending of €1 also generates €1. This public expenditure  can stimulate additional private-sector investment, whereby every euro of public investment in basic biomedical research attracts an average of 7 euros in private sector pharmaceutical R&D within eight years. In Germany, this domestic leverage effect is 3.7 times the OECD average, directly reinforcing a healthcare industry that employs nearly eight million people.
• Strengthening research ecosystems: While the scientific focus targets conditions heavily prevalent in LMICs, approximately 54 percent of the research funds provided by Germany remains within domestic institutions. This funding increases the global visibility of German universities and promotes the dissemination of innovative methods, such as participatory research approaches. 
• International cooperation and diplomacy: Long-term scientific partnerships can strengthen trust, foster dialogue, and support evidence-informed international cooperation.
• Preparedness and resilience: The financial realities between proactive and reactive measures are striking. Proactive pandemic preparedness offers maximum value for money. Experts estimate that a global public investment of roughly 3.9 billion euros per year to strengthen local health systems and fund preventative R&D are sufficient to structurally prevent future pandemics. In contrast, a reactive response to a fully uncontained global health crisis results substantial economic and societal costs of 600 billion euros annually.

The report is complemented by case studies illustrating how innovations developed through global health partnerships have been applied to improve health system performance in Germany and other high-income countries:

1. SORMAS (Surveillance Outbreak Response Management System): Originally developed in partnership with West African institutions during the 2014/15 Ebola outbreak, this digital surveillance tool was operable during the pandemic across more than 80 percent of German public health authorities, proving how tools built for resource-limited settings deliver cost-effective domestic infrastructure solutions.
2. mRNA Vaccine Platforms: Decades of reliable basic research funding via the Federal Ministry of Research, Technology, and Space (BMFTR), the German Research Foundation (DFG), and the EU enabled domestic biotech pioneers to achieve the leap from basic science to global application in a short timeframe. This single biomedical breakthrough alone prevented an estimated 20 million deaths worldwide in 2021.
3. Malaria Research Synergies: Collaborative clinical trials conducted by German universities and the Lambaréné Medical Research Center (CERMEL) in Gabon provided the essential evidence required for the WHO’s recommendation on malaria vaccination in 2021. Crucially, the innovations behind these malaria studies led directly to the development of the AS01 vaccine adjuvant and the ChAdOx1 platform, which are now used globally to protect adults against shingles, respiratory syncytial virus (RSV), and emerging infectious threats.